GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Private equity sees attractive demand and growth opportunities within the fragmented healthcare cost containment service ...

Breaking the link between prescription drug list prices and compensation to middlemen like pharmacy benefit managers (PBMs) ...

Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

With increasing global demand for advanced weight loss solutions, Canadian consumers now have a new way to access the recently approved obesity treatment Zepbound. Online pharmacy DutyFreeMeds.com is ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...